Streetbeat News

Price Targets

SYK

B of A Securities analyst Travis Steed has upgraded Stryker (NYSE:SYK) from Neutral to Buy and announced a price target of $315.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2023 | 10:51 am

WWD

TD Cowen analyst Gautam Khanna has upgraded Woodward (NASDAQ:WWD) from Market Perform to Outperform and raised the price target from $135 to $160.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2023 | 10:50 am

ITRG

HC Wainwright & Co. analyst Heiko Ihle maintains a 'Buy' rating on Integra Resources (AMEX:ITRG) and raises the price target from $3.25 to $4.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2023 | 10:19 am

SLRN

HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Acelyrin (NASDAQ:SLRN) with a Buy rating and announces a price target of $44.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2023 | 10:18 am

SOUN

HC Wainwright & Co. analyst Scott Buck has initiated coverage on SoundHound AI (NASDAQ:SOUN) with a Buy rating and a price target of $5.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2023 | 10:18 am

SPRO

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Spero Therapeutics (NASDAQ:SPRO) and maintained a $7 price target.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2023 | 10:15 am

RLYB

HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a 'Buy' rating on Rallybio (NASDAQ:RLYB) and maintained an $18 price target.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2023 | 10:14 am

GMAB

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Genmab (NASDAQ:GMAB) and maintained a $51 price target.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2023 | 10:13 am

NAPA

BMO Capital analyst Andrew Strelzik has initiated coverage on Duckhorn Portfolio (NYSE:NAPA) with a Market Perform rating and a price target of $14.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2023 | 10:10 am

SANA

Citigroup analyst Samantha Semenkow has initiated coverage on Sana Biotechnology (NASDAQ:SANA) with a Buy rating and a price target of $8.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2023 | 10:10 am